← All trials
NCT06558188
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2025
- Primary completion
- Apr 1, 2027
- Completion date
- Jan 1, 2028
- First posted
- Aug 16, 2024
- Last posted
- Oct 18, 2024
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityOfficial
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Collaborator
- Harvard UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.